Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations

被引:28
作者
Harrison, CJ
Radford-Weiss, I
Ross, F
Rack, K
le Guyader, G
Vekemans, M
Macintyre, E
机构
[1] Hop Necker Enfants Malad, Lab Cent Hematol & Cytogenet, Paris, France
[2] Wessex Reg Genet Lab, Salisbury, Wilts, England
关键词
D O I
10.1016/S0165-4608(98)00244-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The translocation (8;21)(q22;q22) is associated with acute myeloblastic leukemia (AML M2). The accurate detection of this chromosomal rearrangement is vital due to its association with a favorable prognosis. Variant translocations exist; these may be hidden within an unusual or complex karyotype. Tn such cases, it is often difficult to confirm the presence of t(8;21)(q22;q22) by conventional cytogenetic analysis alone. The molecular detection of the AML1/ETO fusion gene is possible by reverse transcriptase polymerase chain reaction (RT-PCR) or dual-color fluorescence in situ hybridization (FISH) using probes specific for AML1 and ETO. Four cases of AML M2, with unusual or complex structural chromosomal abnormalities, without cytogenetic evidence of the classical t(8;21)(q22;q22), were studied by FISH. Two were AML1/ETO positive bq RT-PCR, one showed a rearrangement by AML1 by Southern analysis, and the fourth had morphological features characteristic of t(8;21). The FISH results showed a co-localization of one AML1 and one ETO signal in interphase and metaphase nuclei in all four cases, demonstrating the presence of variant t(8;21)(q22;q22) rearrangements. There fore, FISH analysis with the AML1 and ETO probes is extremely valuable, in cases of AML M2, because of its ability to reveal masked t(8;21)(q22;q22) translocations and thus quickly confirm the diagnosis, allowing patients to be assigned to the correct risk group in terms of treatment. (C) Elsevier Science Inc., 1999, All rights reserved.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 26 条
[1]   Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: Correlation with cytogenetics, morphology and immunophenotype [J].
Andrieu, V ;
RadfordWeiss, I ;
Troussard, X ;
Chane, C ;
Valensi, F ;
Guesnu, M ;
Haddad, E ;
Viguier, F ;
Dreyfus, F ;
Varet, B ;
Flandrin, G ;
Macintyre, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) :855-865
[2]  
[Anonymous], [No title captured]
[3]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[4]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[5]   Secondary acute myeloblastic leukemia with t(16;21)(q24;q22) involving the AML1 gene [J].
Berger, R ;
LeConiat, M ;
Romana, SP ;
Jonveaux, P .
HEMATOLOGY AND CELL THERAPY, 1996, 38 (02) :183-186
[6]  
BERGER R, 1982, BLOOD, V59, P171
[7]  
BERNHEIM A, 1990, CANCER GENET CYTOGEN, V44, P169
[8]  
ERICKSON P, 1992, BLOOD, V80, P1825
[9]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[10]   Development of an interphase fluorescent in situ hybridization (FISH) test to detect t(8;21) in AML patients [J].
Hagemeijer, A ;
de Klein, A ;
Wijsman, J ;
van Meerten, E ;
de Greef, GE ;
Sacchi, N .
LEUKEMIA, 1998, 12 (01) :96-101